Peptides DB
Research-centric peptide and protocol reference hub

PT-141 (Bremelanotide) record · updated 20h ago

Neuro & moodInflammation & immuneGrade A · human clinicalResearch use only
All 14 studiesJump to the evidenceCompare
What is PT-141 (Bremelanotide) used for?

PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.

How it works: Melanocortin receptor agonist

Primarily researched for · Neuro & moodRoute · Subcutaneous injection

Development stage

where PT-141 (Bremelanotide) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 10 registered trials. It describes the research record, not a recommendation.

Identity
NamePT-141 (Bremelanotide)
Chain length—
Molecular weight1,025.2 Da
FormulaC50H68N14O10
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 9941379. No verified residue count for this compound.

Pharmacology
MechanismMelanocortin receptor agonist
RouteSubcutaneous injection
Half-life~2.7 hours
Time to peak1 hour
DurationUp to 24 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 7, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular2 / 3 / 1
Highest trial phasePreclinical
Years covered2010–2026
Latest study18d ago
Publication history
20102026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Sexual arousal: Sex matters.
TakeawayNot reported in abstract.
—2017Title only0.20
Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
FindingTerminal elimination half-life of 24 h (3 mg/kg), 34 h (6 mg/kg), and 53 h (12 mg/kg).
Human2026Full text read0.90
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.
Finding150 mg/kg PCZ in mice, n=126; 350 mg/kg PCZ in monkeys, n=10.
Animal2026Full text read0.80
Risk stratification for in-hospital mortality in sepsis-associated acute kidney injury patients receiving continuous renal replacement therapy: an interpretable, externally validated machine learning study.
FindingAUC of 0.890 in training cohort, n=1217.
Human2026Full text read0.80
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
FindingCoefficient of determination (r²) of 0.9993 over the concentration range of 25-150 µg mL-1.
review2026Full text read0.70
Incorporation of Three Extracyclic Arginine Residues into a Melanocortin Macrocyclic Agonist (c[Pro-His-DPhe-Arg-Trp-Dap-Lys(Arg-Arg-Arg-Ac)-DPro]) Decreases Food Intake When Administered Intrathecally or Subcutaneously Compared to a Macrocyclic Ligand Lacking Extracyclic Arginine Residues (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro)].
FindingNot reported in abstract.
Animal2024Partial text0.40
Quantification of "Mercy Sex" in Heterosexual Women.
FindingWomen engaged in 'mercy sex' approximately 2.5 times/month.
review2026Full text read0.70
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
FindingNot reported in abstract.
review2026Full text read0.80
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
FindingNot reported in abstract.
Animal2025Full text read0.70
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
FindingNot reported in abstract.
review2026Full text read0.80
Semantic Scholar search for PT-141 (Bremelanotide)
TakeawayNot reported in abstract.
—2010Title only0.00
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.
TakeawayBremelanotide and other FDA-approved drugs may have potential as inhibitors of SARS-CoV-2 proteins, but experimental validation is necessary before considering clinical application.
In vitro2025Title only0.30

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching PT-141 (Bremelanotide) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much PT-141 (Bremelanotide) is discussed should be drawn from it.

Articles mentioning PT-141 (Bremelanotide)